BSX logo

Boston Scientific Corporation Stock Price

NYSE:BSX Community·US$153.9b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 85 Fair Values set on narratives written by author

BSX Share Price Performance

US$102.39
17.29 (20.32%)
18.8% undervalued intrinsic discount
US$126.14
Fair Value
US$102.39
17.29 (20.32%)
17.5% undervalued intrinsic discount
US$124.14
Fair Value
Price US$102.39
AnalystConsensusTarget US$124.14

BSX Community Narratives

AnalystConsensusTarget·
Fair Value US$126.14 n/aintrinsic discount

Future Growth Plans And Acquisitions Will Drive Broader Market Expansion

1users have liked this narrative
0users have commented on this narrative
38users have followed this narrative

Snowflake Analysis

Solid track record with adequate balance sheet.

1 Risk
3 Rewards

Boston Scientific Corporation Key Details

US$19.3b

Revenue

US$6.0b

Cost of Revenue

US$13.3b

Gross Profit

US$10.5b

Other Expenses

US$2.8b

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
1.88
68.90%
14.42%
53.1%
View Full Analysis

About BSX

Founded
1979
Employees
53000
CEO
Michael Mahoney
WebsiteView website
www.bostonscientific.com

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, proprietary programming software, radiofrequency ablation, indirect decompression systems, and intraosseous nerve ablation and deep brain stimulation systems. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat, and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Recent BSX News & Updates

Recent updates

No updates